vs
卡骆驰（CROX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
卡骆驰的季度营收约是Revvity的1.2倍（$921.5M vs $772.1M），卡骆驰净利率更高（14.9% vs 12.7%，领先2.2%），Revvity同比增速更快（5.9% vs -1.7%），Revvity自由现金流更多（$161.8M vs $-98.9M），过去两年Revvity的营收复合增速更高（9.0% vs -8.9%）
卡骆驰（Crocs）是总部位于美国科罗拉多州布鲁姆菲尔德的鞋履企业，主打生产、销售旗下同名品牌的泡沫鞋履产品。其标志性鞋款虽被品牌称为“木屐”，但和传统木屐不同，不含木质材料，凭借舒适轻便的特性受到全球消费者喜爱。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CROX vs RVTY — 直观对比
营收规模更大
CROX
是对方的1.2倍
$772.1M
营收增速更快
RVTY
高出7.5%
-1.7%
净利率更高
CROX
高出2.2%
12.7%
自由现金流更多
RVTY
多$260.7M
$-98.9M
两年增速更快
RVTY
近两年复合增速
-8.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $921.5M | $772.1M |
| 净利润 | $137.6M | $98.4M |
| 毛利率 | 56.8% | — |
| 营业利润率 | 21.8% | 14.5% |
| 净利率 | 14.9% | 12.7% |
| 营收同比 | -1.7% | 5.9% |
| 净利润同比 | -14.1% | 3.9% |
| 每股收益（稀释后） | $2.71 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CROXRVTY
| Q1 26 | $921.5M | — | ||
| Q4 25 | $957.6M | $772.1M | ||
| Q3 25 | $996.3M | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $937.3M | $664.8M | ||
| Q4 24 | $989.8M | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M |
净利润CROXRVTY
| Q1 26 | $137.6M | — | ||
| Q4 25 | $105.2M | $98.4M | ||
| Q3 25 | $145.8M | $46.7M | ||
| Q2 25 | $-492.3M | $53.9M | ||
| Q1 25 | $160.1M | $42.2M | ||
| Q4 24 | $368.9M | $94.6M | ||
| Q3 24 | $199.8M | $94.4M | ||
| Q2 24 | $228.9M | $55.4M |
毛利率CROXRVTY
| Q1 26 | 56.8% | — | ||
| Q4 25 | 54.7% | — | ||
| Q3 25 | 58.5% | 53.6% | ||
| Q2 25 | 61.7% | 54.5% | ||
| Q1 25 | 57.8% | 56.5% | ||
| Q4 24 | 57.9% | — | ||
| Q3 24 | 59.6% | 56.3% | ||
| Q2 24 | 61.4% | 55.7% |
营业利润率CROXRVTY
| Q1 26 | 21.8% | — | ||
| Q4 25 | 15.3% | 14.5% | ||
| Q3 25 | 20.8% | 11.7% | ||
| Q2 25 | -37.2% | 12.6% | ||
| Q1 25 | 23.8% | 10.9% | ||
| Q4 24 | 20.2% | 16.3% | ||
| Q3 24 | 25.4% | 14.3% | ||
| Q2 24 | 29.3% | 12.4% |
净利率CROXRVTY
| Q1 26 | 14.9% | — | ||
| Q4 25 | 11.0% | 12.7% | ||
| Q3 25 | 14.6% | 6.7% | ||
| Q2 25 | -42.8% | 7.5% | ||
| Q1 25 | 17.1% | 6.4% | ||
| Q4 24 | 37.3% | 13.0% | ||
| Q3 24 | 18.8% | 13.8% | ||
| Q2 24 | 20.6% | 8.0% |
每股收益（稀释后）CROXRVTY
| Q1 26 | $2.71 | — | ||
| Q4 25 | $1.79 | $0.86 | ||
| Q3 25 | $2.70 | $0.40 | ||
| Q2 25 | $-8.82 | $0.46 | ||
| Q1 25 | $2.83 | $0.35 | ||
| Q4 24 | $6.25 | $0.77 | ||
| Q3 24 | $3.36 | $0.77 | ||
| Q2 24 | $3.77 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $130.9M | $919.9M |
| 总债务越低越好 | $1.3B | — |
| 股东权益账面价值 | $1.4B | $7.3B |
| 总资产 | $4.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.93× | — |
8季度趋势，按日历期对齐
现金及短期投资CROXRVTY
| Q1 26 | $130.9M | — | ||
| Q4 25 | $130.4M | $919.9M | ||
| Q3 25 | $154.0M | $931.4M | ||
| Q2 25 | $200.6M | $991.8M | ||
| Q1 25 | $166.5M | $1.1B | ||
| Q4 24 | $180.5M | $1.2B | ||
| Q3 24 | $186.1M | $1.2B | ||
| Q2 24 | $167.7M | $2.0B |
总债务CROXRVTY
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CROXRVTY
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.4B | $7.4B | ||
| Q2 25 | $1.4B | $7.6B | ||
| Q1 25 | $2.0B | $7.6B | ||
| Q4 24 | $1.8B | $7.7B | ||
| Q3 24 | $1.7B | $7.9B | ||
| Q2 24 | $1.7B | $7.9B |
总资产CROXRVTY
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.2B | $12.2B | ||
| Q3 25 | $4.3B | $12.1B | ||
| Q2 25 | $4.5B | $12.4B | ||
| Q1 25 | $5.1B | $12.4B | ||
| Q4 24 | $4.8B | $12.4B | ||
| Q3 24 | $4.7B | $12.8B | ||
| Q2 24 | $4.7B | $13.4B |
负债/权益比CROXRVTY
| Q1 26 | 0.93× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-98.9M | $161.8M |
| 自由现金流率自由现金流/营收 | -10.7% | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $642.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CROXRVTY
| Q1 26 | — | — | ||
| Q4 25 | $252.5M | $182.0M | ||
| Q3 25 | $239.3M | $138.5M | ||
| Q2 25 | $285.8M | $134.3M | ||
| Q1 25 | $-67.2M | $128.2M | ||
| Q4 24 | $321.9M | $174.2M | ||
| Q3 24 | $296.9M | $147.9M | ||
| Q2 24 | $401.2M | $158.6M |
自由现金流CROXRVTY
| Q1 26 | $-98.9M | — | ||
| Q4 25 | $246.4M | $161.8M | ||
| Q3 25 | $226.2M | $120.0M | ||
| Q2 25 | $269.2M | $115.5M | ||
| Q1 25 | $-82.6M | $112.2M | ||
| Q4 24 | $303.4M | $149.8M | ||
| Q3 24 | $278.8M | $125.6M | ||
| Q2 24 | $384.2M | $136.6M |
自由现金流率CROXRVTY
| Q1 26 | -10.7% | — | ||
| Q4 25 | 25.7% | 21.0% | ||
| Q3 25 | 22.7% | 17.2% | ||
| Q2 25 | 23.4% | 16.0% | ||
| Q1 25 | -8.8% | 16.9% | ||
| Q4 24 | 30.7% | 20.5% | ||
| Q3 24 | 26.3% | 18.4% | ||
| Q2 24 | 34.6% | 19.7% |
资本支出强度CROXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 2.6% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 1.6% | 2.4% | ||
| Q4 24 | 1.9% | 3.4% | ||
| Q3 24 | 1.7% | 3.3% | ||
| Q2 24 | 1.5% | 3.2% |
现金转化率CROXRVTY
| Q1 26 | — | — | ||
| Q4 25 | 2.40× | 1.85× | ||
| Q3 25 | 1.64× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | -0.42× | 3.03× | ||
| Q4 24 | 0.87× | 1.84× | ||
| Q3 24 | 1.49× | 1.57× | ||
| Q2 24 | 1.75× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CROX
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
